Steven B. Abramson, MD
Executive Vice President and Vice Dean for Education, Faculty, and Academic Affairs
Dr. Steven B. Abramson, executive vice president and vice dean for education, faculty, and academic affairs, is the chair of the Department of Medicine and a professor of medicine and pathology. As vice dean, Dr. Abramson oversees faculty affairs, including appointments, promotions, and tenure issues. Additionally, his office oversees undergraduate, graduate, and postgraduate education, continuing medical education, precollege programs, the admissions process, and NYU Grossman School of Medicine’s accreditation.
Dr. Abramson previously served in the Dean’s Office as associate dean for curriculum, vice dean for medical education, and associate dean for clinical research. As vice dean, he led the Task Force on Curriculum Reform, which resulted in the implementation of Curriculum for the 21st Century (C21) at NYU Grossman School of Medicine.
A summa cum laude, Phi Beta Kappa graduate of Dartmouth College, Dr. Abramson earned his MD from Harvard Medical School, and was elected to the Alpha Omega Alpha honor society. He arrived at NYU Langone and NYC Health + Hospitals/Bellevue for his internship in 1974 and later served as chief resident in medicine. With training in rheumatology, Dr. Abramson joined the NYU Langone faculty in 1979 and rose to the rank of professor in 1996.
In addition to his role in medical education, Dr. Abramson has experience in both basic science and clinical research in the field of inflammation and arthritis, and has published more than 200 papers on these and related topics. He is a co-editor of the journal Arthritis & Rheumatism, a former member of the Rheumatology Board of the American Board of Internal Medicine, past president of the Osteoarthritis Research Society International, and former chairman of the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA). Dr. Abramson was named by the American College of Rheumatology (ACR) board of directors as the first chair of the ACR–FDA Drug Safety Committee. He is also a current member of the Skeletal Biology Structure and Regeneration Study Section of the National Institutes of Health (NIH).